Healthcare / Drug Manufacturers - Specialty & GenericKSE
$8270.00
-320.00 (-3.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-11.9B · quality 27.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$107.4B
P/E
N/A
•EV/EBITDA
13.1x
↑ROE
-0.8%
↓Gross Margin
29.7%
↓Debt/Equity
1.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.5%
FCF CAGR
—
FCF margin
-2.2%
FCF / Net income
5.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $535.14B · net income $-2.15B · FCF $-11.86B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $535.14B | $535.14B | $507.36B | $522.74B | $543.76B |
| Net Income | $-2.15B | $-2.15B | $-52.56B | $-28.80B | $10.68B |
| EBITDA | $35.51B | $35.51B | $-20.82B | $2.76B | $37.30B |
| EPS | -162.00 | -162.00 | -3819.00 | -2091.00 | 776.00 |
| Gross Margin | 29.7% | 29.7% | 31.0% | 31.8% | 31.9% |
| Operating Margin | 0.6% | 0.6% | 0.1% | 2.4% | 5.2% |
| Net Margin | -0.4% | -0.4% | -10.4% | -5.5% | 2.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.37 | 1.37 | 1.30 | 0.89 | 0.79 |
| Current Ratio | 0.77 | 0.77 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-11.86B | $-11.86B | $-22.19B | $9.80B | $-13.22B |
| Returns | |||||
| ROE | -0.8% | -0.8% | -18.3% | -8.5% | 2.8% |
| Valuation | |||||
| P/E | — | — | — | — | 22.04 |
| EV/EBITDA | 13.05 | 13.05 | — | 172.22 | 13.32 |
| P/B | 0.40 | 0.40 | 0.59 | 0.57 | 0.62 |
| Growth & Yield | |||||
| Revenue Growth | 5.5% | 5.5% | -2.9% | -3.9% | — |
| EPS Growth | 95.8% | 95.8% | -82.6% | -369.5% | — |
| Dividend Yield | 2.5% | 2.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-3819.00 → -162.00
Residual
-28.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.